MX2021010402A - Tratamiento de la hidradenitis supurativa. - Google Patents

Tratamiento de la hidradenitis supurativa.

Info

Publication number
MX2021010402A
MX2021010402A MX2021010402A MX2021010402A MX2021010402A MX 2021010402 A MX2021010402 A MX 2021010402A MX 2021010402 A MX2021010402 A MX 2021010402A MX 2021010402 A MX2021010402 A MX 2021010402A MX 2021010402 A MX2021010402 A MX 2021010402A
Authority
MX
Mexico
Prior art keywords
treatment
hidradenitis suppurativa
alpha antibody
suppurativa
hidradenitis
Prior art date
Application number
MX2021010402A
Other languages
English (en)
Spanish (es)
Inventor
Stanley A Kim
Evangelos J Giamarellos-Bourboulis
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021010402A publication Critical patent/MX2021010402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021010402A 2019-02-28 2020-02-27 Tratamiento de la hidradenitis supurativa. MX2021010402A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811696P 2019-02-28 2019-02-28
PCT/US2020/020115 WO2020176738A1 (en) 2019-02-28 2020-02-27 Anti-il-alpha antibody for the treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
MX2021010402A true MX2021010402A (es) 2021-09-14

Family

ID=70110308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010402A MX2021010402A (es) 2019-02-28 2020-02-27 Tratamiento de la hidradenitis supurativa.

Country Status (11)

Country Link
US (1) US20200277370A1 (https=)
EP (1) EP3930752A1 (https=)
JP (1) JP2022523530A (https=)
KR (1) KR20210134927A (https=)
CN (1) CN113905760A (https=)
AU (1) AU2020228299A1 (https=)
BR (1) BR112021016845A2 (https=)
CA (1) CA3131011A1 (https=)
MX (1) MX2021010402A (https=)
TW (1) TW202045537A (https=)
WO (1) WO2020176738A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285409B1 (en) 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS

Also Published As

Publication number Publication date
US20200277370A1 (en) 2020-09-03
AU2020228299A1 (en) 2021-09-09
CA3131011A1 (en) 2020-09-03
EP3930752A1 (en) 2022-01-05
CN113905760A (zh) 2022-01-07
TW202045537A (zh) 2020-12-16
KR20210134927A (ko) 2021-11-11
JP2022523530A (ja) 2022-04-25
BR112021016845A2 (pt) 2021-10-19
WO2020176738A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
MX2021010402A (es) Tratamiento de la hidradenitis supurativa.
JOP20220163B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
PH12020551726A1 (en) Treatment of atopic dermatitis
MX2020009842A (es) Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
EP4696301A3 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
PH12021552521A1 (en) Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
PH12022551468A1 (en) Compounds active towards nuclear receptors
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2022012967A (es) Tratamiento de la hidradenitis supurativa.
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
WO2019204332A3 (en) Pak4 inhibitors and methods of use
MX381433B (es) Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.